Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

Inclusion Criteria:

Completed the 12-week treatment period in 1 of the 2 parent studies (Study DMVT-505-3001 or Study DMVT-505-3002);
Male and female subjects
Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance while on the study, and for at least 4 weeks after the last exposure to study treatment
Capable of giving written informed consent

Exclusion Criteria:

Used a prohibited concomitant product or procedure to treat psoriasis during parent study
Had a serious adverse event (SAE) that was potentially related to treatment or experienced an adverse event (AE) that led to permanent discontinuation of treatment in the parent study
History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with the subject's completion of the study
Known hypersensitivity to tapinarof